- Home
- ACRV vs LVTX Comparison
ACRV vs LVTX Comparison
Compare ACRV & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- LVTX
- Stock Information
- Founded
- ACRV 2018
- LVTX 2016
- Country
- ACRV United States
- LVTX Netherlands
- Employees
- ACRV N/A
- LVTX N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ACRV Health Care
- LVTX Health Care
- Exchange
- ACRV Nasdaq
- LVTX Nasdaq
- Market Cap
- ACRV 47.8M
- LVTX 40.0M
- IPO Year
- ACRV 2022
- LVTX 2021
- Fundamental
- Price
- ACRV $2.09
- LVTX $1.61
- Analyst Decision
- ACRV Buy
- LVTX Hold
- Analyst Count
- ACRV 6
- LVTX 4
- Target Price
- ACRV $17.75
- LVTX $1.58
- AVG Volume (30 Days)
- ACRV 464.1K
- LVTX 576.3K
- Earning Date
- ACRV 11-12-2025
- LVTX 12-09-2025
- Dividend Yield
- ACRV N/A
- LVTX N/A
- EPS Growth
- ACRV N/A
- LVTX N/A
- EPS
- ACRV N/A
- LVTX N/A
- Revenue
- ACRV N/A
- LVTX $4,990,000.00
- Revenue This Year
- ACRV N/A
- LVTX N/A
- Revenue Next Year
- ACRV $805.34
- LVTX N/A
- P/E Ratio
- ACRV N/A
- LVTX N/A
- Revenue Growth
- ACRV N/A
- LVTX N/A
- 52 Week Low
- ACRV $1.05
- LVTX $0.85
- 52 Week High
- ACRV $8.74
- LVTX $2.06
- Technical
- Relative Strength Index (RSI)
- ACRV 65.95
- LVTX 59.24
- Support Level
- ACRV $1.92
- LVTX $1.53
- Resistance Level
- ACRV $2.05
- LVTX $1.63
- Average True Range (ATR)
- ACRV 0.15
- LVTX 0.07
- MACD
- ACRV 0.01
- LVTX 0.01
- Stochastic Oscillator
- ACRV 97.70
- LVTX 86.87
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.